AstraZeneca is buying Fusion Pharmaceuticals for an initial sum of $2 billion as part of a plan to accelerate the development of next-generation radioconjugates to treat cancer.
AstraZeneca is buying Fusion Pharmaceuticals for an initial sum of $2 billion as part of a plan to accelerate the development of next-generation radioconjugates to treat cancer.